Selegiline reduces daytime sleepiness in patients with Parkinson's disease,Brain and Behavior

当前位置： X-MOL 学术 › Brain Behav. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Selegiline reduces daytime sleepiness in patients with Parkinson's disease
Brain and Behavior ( IF 2.6 ) Pub Date : 2021-03-23 , DOI: 10.1002/brb3.1880
Marco Gallazzi ₁ , Marco Mauri _{1,

2} , Maria Laura Bianchi ₃ , Giulio Riboldazzi ₄ , Lucia Princiotta Cariddi _{1,

2} , Federico Carimati ₁ , Valentina Rebecchi ₁ , Maurizio Versino _{1,

2}

Affiliation

Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence.

中文翻译：